Currently, an estimated 80-90 million people in the U.S. have diagnosed or undiagnosed nonalcoholic fatty liver disease (NAFLD). Among these, up to 20 million could have non-alcoholic steatohepatitis (NASH), with as many as four-six million people projected to have advanced fibrosis, or scarring
NASH is often called a ‘silent killer’ since patients typically don’t exhibit symptoms until the disease has progressed to the point of serious organ damage.
Dr. Chuck Cooper, Chief Medical Officer, Siemens Healthcare Diagnostics at Siemens Healthineers discusses how this new test can help assess the risk of NASH progressing in patients.
Paid for by: Siemens Healthineers
